Reshma Kewalramani
CEO & President at Vertex Pharmaceuticals Incorporated
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Vertex Pharmaceuticals Incorporated, 3 years.
Vertex Pharmaceuticals Incorporated
Director · CEO & President
Ginkgo Bioworks Holdings Inc.
Director
Chief executive roles
Vertex Pharmaceuticals Incorporated
· CEO & President
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 8, 2024 | Vertex Pharmaceuticals Incorporated | Open-market sale | −15,198 | $515.00 | $7,826,970 |
| Jul 30, 2024 | Vertex Pharmaceuticals Incorporated | Open-market sale | −15,202 | $505.00 | $7,677,010 |
| Jul 22, 2024 | Vertex Pharmaceuticals Incorporated | Open-market sale | −15,202 | $497.00 | $7,555,394 |
| Jun 12, 2024 | Ginkgo Bioworks Holdings Inc. | Option exercise | +105,263 | — | — |
| May 24, 2024 | Vertex Pharmaceuticals Incorporated | Option exercise | +1,565 | $187.53 | $293,484 |
| May 24, 2024 | Vertex Pharmaceuticals Incorporated | Open-market sale | −1,565 | $457.00 | $715,205 |
| May 20, 2024 | Vertex Pharmaceuticals Incorporated | Open-market sale | −15,202 | $447.00 | $6,795,294 |
| Feb 23, 2024 | Vertex Pharmaceuticals Incorporated | Shares withheld for tax | −9,386 | $431.79 | $4,052,781 |
| Feb 20, 2024 | Vertex Pharmaceuticals Incorporated | Shares withheld for tax | −7,019 | $420.58 | $2,952,051 |
| Feb 16, 2024 | Vertex Pharmaceuticals Incorporated | Shares withheld for tax | −9,359 | $424.01 | $3,968,310 |
| Feb 9, 2024 | Vertex Pharmaceuticals Incorporated | Shares withheld for tax | −8,255 | $422.74 | $3,489,719 |
| Feb 7, 2024 | Vertex Pharmaceuticals Incorporated | Grant or award | +20,327 | — | — |
| Feb 6, 2024 | Vertex Pharmaceuticals Incorporated | Grant or award | +14,516 | — | — |
| Feb 6, 2024 | Vertex Pharmaceuticals Incorporated | Grant or award | +26,972 | — | — |
| Dec 15, 2023 | Vertex Pharmaceuticals Incorporated | Option exercise | +3,058 | $155.57 | $475,733 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.